Sijudi Pharmaceutical Co., Ltd. (01244): has fully received from SELLAS a total of HKD 7.983 million for the relevant expenses incurred by the company.

Zhitong Finance APP News, Sidley's Pharmaceutical Co., Ltd. (01244) announced that it has released an update regarding the ongoing dispute case with SELLAS Life Sciences Group, Inc. A sole arbitrator has made a final ruling, completely dismissing all arbitration claims put forth by SELLAS, and has ruled that SELLAS must bear the relevant expenses arising from this arbitration, totaling HKD 7.983 million. The companys board of directors is pleased to announce that the company has received the full amount stated above, and this arbitration ruling has been fully executed.